Shionogi

-6.38%

Shionogi is a Japanese pharmaceutical company that was founded in 1878. It is headquartered in Osaka, Japan and has a presence in over 50 countries worldwide. The company's main focus is on the research, development, and commercialization of pharmaceutical products in various therapeutic areas, including infectious diseases, oncology, and cardiovascular diseases.
Shionogi is known for its innovative research and development programs, with a strong emphasis on tackling global health challenges. Some of the company's most notable research achievements include the development of new treatments for HIV/AIDS, tuberculosis, and influenza.
In addition to its pharmaceutical business, Shionogi also has a presence in the consumer health and microbiome businesses. It has partnerships and collaborations with other pharmaceutical companies, research institutions, and universities to develop new treatments and technologies.
The company's mission is to provide innovative medicines and solutions to improve the health and wellbeing of people worldwide. It is committed to responsible and ethical business practices, as well as sustainability and environmental conservation.
Currently, Shionogi is focused on expanding its global presence and advancing its pipeline of drug candidates to address unmet medical needs. It also continues to invest in research and development, with the goal of bringing new and improved treatments to patients in need.

1. Long History and Strong Reputation: Shionogi has a long history dating back to 1878. It is known for its strong track record of developing and marketing innovative medicines in Japan and globally.
2. Focus on Infectious Diseases: Shionogi is committed to developing treatments for infectious diseases such as HIV, influenza, and antibiotic-resistant infections, which are often neglected by other pharmaceutical companies.
3. Diversified Portfolio: Shionogi has a diversified portfolio, with products ranging from prescription drugs to over-the-counter medicines, diagnostics, and medical devices.
4. International Presence: Shionogi has a strong presence in the international market, with operations in North America, Europe, and Asia. This global reach allows the company to access new markets and collaborate with international partners.
5. Research and Development: The company invests heavily in research and development to bring new and innovative medicines to market. Shionogi's R&D efforts have led to the development of breakthrough drugs in various therapeutic areas.
6. Strong Pipeline: Shionogi has a robust pipeline of potential new medications, with over 40 products in development. This ensures a steady stream of new products to drive growth in the future.
7. Corporate Social Responsibility: Shionogi is committed to being a socially responsible company, focusing on ethical and responsible business practices, environmental sustainability, and supporting the communities in which it operates.
8. Strong Financial Performance: Shionogi has a strong financial track record, consistently delivering profits and increased revenue over the years. This financial stability allows the company to continue investing in research and development and expanding its global presence.
9. Award-Winning Innovations: Shionogi's commitment to innovation has been recognized by various prestigious awards, such as the Nikkei Superior Products and Services Award and the Japan Bioindustry Association Award.
10. Employee Satisfaction: Shionogi is known for its positive work culture and employee satisfaction. The company has been recognized as one of the best places to work in Japan and globally, promoting diversity, inclusion, and employee well-being.

The Shionogi company is a Japanese pharmaceutical company. Its business model revolves around researching, developing, manufacturing, and marketing prescription and over-the-counter medicines. Its focus is primarily on treatments for infectious diseases, pain, and cancer.
The company also has a research and development pipeline for new drugs and continuously invests in partnerships and collaborations to further expand its product portfolio.
Additionally, Shionogi has a global presence, with operations in Asia, Europe, and the United States, selling its products in more than 90 countries.
Furthermore, the company also has a strong commitment to corporate social responsibility, including efforts to reduce its environmental impact and provide access to medicine in underserved communities.
In summary, Shionogi's business model involves the development and production of innovative pharmaceutical products, strategic partnerships and collaborations, and a focus on social responsibility.

- Shionogi & Co., Ltd. is a Japanese pharmaceutical company founded in 1878 by Gisaburo Shiono in Osaka, Japan.
- The company’s name comes from the founder’s last name, Shiono, and the Japanese word gi, meaning science.
- Shionogi is the second-oldest Japanese pharmaceutical company, after Takeda Pharmaceuticals.
- The company’s current headquarters is located in Osaka, with additional offices and research facilities in other cities in Japan, as well as in the United States, China, and Europe.
- Shionogi has a diverse portfolio of drugs, including treatments for infectious diseases, cardiovascular disorders, and cancer.
- The company is known for developing innovative drugs, especially in the areas of anti-infectives and pain management.
- In 2018, Shionogi partnered with Gilead Sciences to develop and commercialize a new HIV treatment.
- Shionogi has a strong commitment to sustainability and has received recognition for its environmental and social responsibility efforts.
- The company also invests heavily in research and development, with approximately 25% of its revenues allocated to R&D.
- In 2021, Shionogi announced that its flu treatment, Xofluza, had received the first global approval for over-the-counter use. It is the first prescription-to-OTC switch for a flu treatment in Japan.